ProPhase Labs (NASDAQ:PRPH) Stock Rating Upgraded by Wall Street Zen

ProPhase Labs (NASDAQ:PRPH) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of ProPhase Labs in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, ProPhase Labs presently has an average rating of “Sell”.

ProPhase Labs Trading Down 15.4%

Shares of ProPhase Labs stock opened at $0.52 on Friday. The company has a market capitalization of $2.40 million, a P/E ratio of -1.33 and a beta of -0.65. The stock has a fifty day simple moving average of $0.28 and a 200 day simple moving average of $0.36. ProPhase Labs has a 12-month low of $0.50 and a 12-month high of $9.35. The company has a current ratio of 0.14, a quick ratio of 0.14 and a debt-to-equity ratio of 0.14.

ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings data on Wednesday, November 19th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05). ProPhase Labs had a negative net margin of 825.01% and a negative return on equity of 482.05%. The company had revenue of $0.88 million for the quarter, compared to the consensus estimate of $5.69 million. On average, sell-side analysts anticipate that ProPhase Labs will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ProPhase Labs

Institutional investors have recently added to or reduced their stakes in the stock. Josh Arnold Investment Consultant LLC bought a new stake in ProPhase Labs in the first quarter worth about $100,000. Sykon Capital LLC bought a new position in shares of ProPhase Labs during the 2nd quarter valued at approximately $252,000. Apollon Wealth Management LLC purchased a new stake in shares of ProPhase Labs during the 3rd quarter worth approximately $84,000. Accretive Wealth Partners LLC purchased a new stake in shares of ProPhase Labs during the 3rd quarter worth approximately $114,000. Finally, Susquehanna International Group LLP raised its holdings in shares of ProPhase Labs by 290.1% in the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock worth $182,000 after purchasing an additional 295,899 shares during the period. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.